Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study investigated the role that sensory nerves play in mediating the hormone and glucose metabolic response to endotoxin [
lipopolysaccharide
(
LPS
)]. Adult rats were pretreated subcutaneously with capsaicin to selectively destroy primary sensory afferent nerve fibers. Ten days later, [3-3H]glucose was infused intravenously to assess whole body glucose flux before and after the intravenous injection of Escherichia coli
LPS
(100 micrograms/100 g body wt). Control animals responded to
LPS
with characteristic increases in the plasma concentration of glucose (91%) and lactate (threefold) and elevations in the rates of glucose appearance and disappearance (77%). In capsaicin-treated rats, the maximal
LPS
-induced increase in these parameters was attenuated by 50-60%. In addition, these animals were hypoglycemic at the conclusion of the experiment. Control animals demonstrated early and sustained elevations in circulating levels of corticosterone,
glucagon
, and catecholamines. In contrast, the early
LPS
-induced elevation in epinephrine and norepinephrine, and to a lesser extent
glucagon
, was completely absent or greatly impaired by capsaicin pretreatment. In a separate study, the epinephrine-induced increase in glucose flux was blunted by 75% in capsaicin-treated rats. These data indicate that sensory afferent neurons play a critical role in the early secretory response of
glucagon
and catecholamines, the maintenance of tissue catecholamine responsiveness, and the stimulation of glucose production after
LPS
.
...
PMID:Involvement of capsaicin-sensitive nerves in regulating the hormone and glucose metabolic response to endotoxin. 927 86
Addition of
lipopolysaccharide
plus interferon gamma, tumour necrosis factor alpha and interleukin 1 beta to cultured hepatocytes resulted in the induction of inducible nitric oxide synthase (iNOS) activity as measured by NO3(-)+NO2- formation, the conversion of L-[U-14C]arginine into citrulline and Western blotting of the iNOS protein. The inclusion of 1 microM
glucagon
during the induction period significantly decreased the effect of the cytokines on iNOS activity, the major effect being at the level of the total amount of protein, rather than alterations in substrate supply or covalent modification of the existing protein. In contrast, 1 microM insulin was without effect. The effect of
glucagon
was mediated via cAMP and could be mimicked by the presence of either dibutyryl cAMP or forskolin to activate adenylate cyclase directly. It was rapid in onset and long-lived, a 30 min pretreatment period protecting the cells from the induction of NO synthesis over the next 21 h in the presence of cytokines. Addition of
glucagon
at any time point up to 9 h after treatment of the cells with
lipopolysaccharide
plus the cytokines resulted in a significant inhibition of iNOS activity,
glucagon
being most potent when added during the first 3 h.
...
PMID:Inhibition of cytokine-induced inducible nitric oxide synthase expression by glucagon and cAMP in cultured hepatocytes. 933 67
Culturing hepatocytes with a combination of tumor necrosis factor alpha, interferon gamma, and interleukin 1 beta plus
lipopolysaccharide
resulted in an induction of nitric oxide synthase and concomitant inhibition of both hepatic gluconeogenesis and glycogenolysis. The inhibition of gluconeogenesis was evident both under basal conditions and in cells stimulated acutely with
glucagon
. The stimulation of glycogen mobilization by
glucagon
was largely prevented by the presence of the cytokines. Chronic 24-h treatment of the cells with
glucagon
attenuated the cytokine response on both glucose output and NO formation in the dexamethasone-treated cells. This effect was antagonized by insulin. Inclusion of 1 mM NG-nitro-L-arginine methyl ester or 0.5 mM NG-monomethyl-L-arginine in the incubation abolished the increase in NO2- plus NO3- induced by the cytokine mixture and partially reversed the inhibitory effects on glucose mobilization in the presence of either insulin or
glucagon
, confirming the involvement of NO. In contrast the NO synthase inhibitors had little effect on either gluconeogenesis or glycogenolysis in the presence of dexamethasone alone, indicating that NO is only partially responsible for the inhibitory action of the cytokines, and the extent of its involvement depends upon the influence of other hormonal factors on the pathways. The antioxidant trolox also suppressed the inhibition of glucose release by the cytokines under conditions where nitric oxide synthase inhibitors were ineffective, suggesting that both reactive oxygen intermediates and NO may act as mediators, the relative importance of each depending upon the metabolic status of the cell.
...
PMID:The importance of nitric oxide in the cytokine-induced inhibition of glucose formation by cultured hepatocytes incubated with insulin, dexamethasone, and glucagon. 943 95
This study tested the hypothesis that systemic stressors in rats activate
glucagon
-like peptide-1 (GLP-1)-immunoreactive neurons in the caudal brain stem, including those that project to the paraventricular nucleus of the hypothalamus (PVN). Neural tracer was microinjected into the PVN to retrogradely label brain stem neurons. Seven to ten days later, rats were injected with lithium chloride (LiCl; 50 mg/kg). Additional non-tracer-injected rats were treated with
lipopolysaccharide
(LPS; 100 microgram/kg) or CCK (100 microgram/kg) or were allowed to consume a very large meal. Rats were killed 90-120 min after drug treatment or 30 min after the meal. Brains were processed for immunocytochemical localization of c-Fos (a marker of neuronal activation), GLP-1, and, when appropriate, neural tracer. The majority of GLP-1 neurons were activated to express c-Fos after LiCl, LPS, or CCK treatment, including (in LiCl-treated rats) those projecting to the PVN. In contrast, GLP-1 neurons rarely expressed c-Fos after ingestion of a large meal, despite prominent activation of other brain stem neurons. These results suggest that GLP-1 neurons are uniquely activated in situations of interoceptive stress, and may participate in adaptive hypothalamic stress responses.
...
PMID:Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. 1044 67
We investigated, by a combined in vivo and in vitro approach, the temporal changes of islet nitric oxide synthase (NOS)-derived nitric oxide (NO) and heme oxygenase (HO)-derived carbon monoxide (CO) production in relation to insulin and
glucagon
secretion during acute endotoxemia induced by
lipopolysaccharide
(
LPS
) in mice. Basal plasma
glucagon
, islet cAMP and cGMP content after in vitro incubation, the insulin response to glucose in vivo and in vitro, and the insulin and
glucagon
responses to the adenylate cyclase activator forskolin were greatly increased after
LPS
. Immunoblots demonstrated expression of inducible NOS (iNOS), inducible HO (HO-1), and an increased expression of constitutive HO (HO-2) in islet tissue. Immunocytochemistry revealed a marked expression of iNOS in many beta-cells, but only in single alpha-cells after
LPS
. Moreover, biochemical analysis showed a time dependent and markedly increased production of NO and CO in these islets. Addition of a NOS inhibitor to such islets evoked a marked potentiation of glucose-stimulated insulin release. Finally, after incubation in vitro, a marked suppression of NO production by both exogenous CO and
glucagon
was observed in control islets. This effect occurred independently of a concomitant inhibition of guanylyl cyclase. We suggest that the impairing effect of increased production of islet NO on insulin secretion during acute endotoxemia is antagonized by increased activities of the islet cAMP and HO-CO systems, constituting important compensatory mechanisms against the noxious and diabetogenic actions of NO in endocrine pancreas.
...
PMID:Evaluation of islet heme oxygenase-CO and nitric oxide synthase-NO pathways during acute endotoxemia. 1128 38
This study was performed to investigate blood metabolite, tumor necrosis factor-alpha, and hormone responses to intravenous administration of lipopolysaccharides (2 microg of endotoxin of Escherichia coli 026:B6/kg body weight at times of feeding) in veal calves orally supplemented with arginine (0.25 g/kg of body weight twice daily for 4 d; group GrA) compared with calves not supplemented with arginine (group GrC). Arginine supplementation alone caused a significant rise of plasma arginine, urea, and insulin concentrations, whereas
glucagon
concentrations tended to increase, but there were no significant group differences. Concentrations of triglycerides, NEFA, glucose, protein, albumin, growth hormone, insulin-like growth factor-I, 3.5.3'-triiodothyronine, and thyroxine were not affected by arginine supplementation. Lipopolysaccharide administration alone caused a rise of tumor necrosis-factor-a, lactate, and cortisol concentrations and concentrations of tumor necrosis-factor-a after 1 h, and of triglycerides and urea after 6 h were higher, whereas of glucose after 3 h were lower in GrA than in GrC. Concentrations of NEFA, glucose, protein, albumin, insulin, growth hormone, insulin-like growth factor-I, 3.5.3'-triiodothyronine, and thyroxine were not affected by
lipopolysaccharide
administration. In conclusion, arginine supplementation had selective effects on plasma metabolites and hormones, but barely modified
lipopolysaccharide
effects. Effects of lipopolysaccharides in the postprandial state were different from what is usually seen in the fasted state.
...
PMID:Metabolic and endocrine changes in response to endotoxin administration with or without oral arginine supplementation. 1221 85
Four multiparous lactating cows (175 to 220 d in milk [DIM]) were used in a 4 x 4 Latin square design to assess the effects of four doses (0.0, 0.5, 1.0, and 1.5 microg/kg of body weight) of
lipopolysaccharide
(LPS; Escherichia coli 0111:B4) on performance and plasma metabolite and hormone concentrations. In addition, effects of immune activation on in vitro hepatic metabolic capacity were evaluated in 12 multiparous lactating cows (150 to 220 DIM) infused with 0 (n = 6), 1.0 (n = 4) or 2.0 (n = 2) microg of LPS/kg. Milk production and DMI decreased linearly with LPS dose for 24 h after LPS infusion. Overall mean plasma tumor necrosis factor-alpha, insulin,
glucagon
, and cortisol concentrations increased linearly with LPS dose, and plasma beta-hydroxybutyrate decreased linearly by dose after LPS infusion. Infusion of LPS decreased the insulin:
glucagon
molar ratio, but did not affect plasma concentrations of growth hormone, insulin-like growth factor-1, leptin, or L-(+)-lactate. Plasma concentrations of glucose tended to increase initially and subsequently decrease, and there was a quadratic tendency for increased plasma nonesterified fatty acid concentrations after LPS administration. In vitro hepatic capacity for conversion of [1-(14)C]L-(+)-lactate and [1-(14)C]palmitate, but not [1-(14)C]propionate or [1-(14)C]L-alanine, to CO2 increased after LPS administration. Hepatic capacity to convert [1-(14)C]propionate to glucose tended to increase, but neither esterification nor the conversion of palmitate to acid soluble products was altered by LPS. The LPS infusion resulted in significant changes of endocrine mediators responsible for regulation of energy metabolism of lactating cows and tended to alter subsequent in vitro hepatic metabolic capacity.
...
PMID:Effect of lipopolysaccharide on indices of peripheral and hepatic metabolism in lactating cows. 1467 74
The inducible nitric oxide synthase (iNOS) is stimulated to produce large quantities of nitric oxide (NO) by proinflammatory stimuli, hemorrhagic shock, and a variety of cytokines. We have previously shown that cAMP profoundly inhibits hepatocyte iNOS expression in vitro. In this study, we tested whether
glucagon
, a hormone that increases cAMP in hepatocytes, could regulate hepatic iNOS expression and activity in vivo. Rats were injected intraperitoneally with
lipopolysaccharide
(LPS, 10 mg/kg) and treated with either saline or
glucagon
(500 microg/kg i.p.). Plasma and liver tissue were obtained 6 and 24 h after LPS. LPS induced increased iNOS mRNA, iNOS protein, and plasma levels of nitrite/nitrate that were all significantly decreased by
glucagon
treatment. The reduction in iNOS expression produced by
glucagon
was associated with a reduction in plasma AST and LDH levels, suggesting decreased LPS-induced hepatic injury. These data suggest that
glucagon
may participate in the in vivo regulation of hepatic iNOS expression after proinflammatory stimuli.
...
PMID:Glucagon regulates hepatic inducible nitric oxide synthesis in vivo. 1525 89
Glia play an important role in neurotoxicity in neurodegenerative diseases. In this study, we investigated the expression of
glucagon
-like peptide-1 (GLP-1) and its receptor, and the effects of GLP-1 on
lipopolysaccharide
(
LPS
)-induced IL-1beta mRNA expression and IL-1beta production in glia. GLP-1-like immunoreactivity was observed in amoeboid microglia, but not ramified microglia or astrocytes. GLP-1 binding and GLP-1 receptor mRNA expression were observed in both astrocytes and microglia. GLP-1-induced morphological changes in microglia from the ramified type to the amoeboid type, suggesting an increase in production and release of endogenous GLP-1. GLP-1 prevented the
LPS
-induced IL-1beta mRNA expression, which effect was, in turn, inhibited by pretreatment with SQ22536, an adenylate cyclase inhibitor. GLP-1 also increased cAMP concentration and cAMP response element-binding protein phosphorylation in astrocytes. These results suggest that GLP-1 may be a modulator of inflammation in the central nervous system.
...
PMID:Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. 1672 54
The liver is thought to be involved in the systemic clearance and detoxification of
lipopolysaccharide
(
LPS
). Argininosuccinate synthase (AS), a liver cytosolic urea cycle enzyme, has been found to bind to and inactivate
LPS
and lipid A. To elucidate the participation of AS in the clearance of
LPS
by liver and hepatocytes, we investigated the correlation between AS content and the removal of lipid A and
LPS
in vivo and in vitro, tracing levels of biological activity. A hepatotoxic model in which mice were injected with CCl(4) revealed a significant reduction in lipid A clearance along with liver failure on day 1; total body clearance was changed to 0.534 ml/min from 1.42 ml/min. AS content in liver concomitantly decreased to about half and AS leaked to blood at about 6 microg/ml. Total body clearance of i.v. injected AS was estimated at 0.083 ml/min, which predicted about 24-h leakage of AS after CCl(4) injection. The treatment also reduced the clearance of R-type LPSs to a lesser degree the larger its polysaccharide portion. S-type
LPS
, which has a large O-antigen polysaccharide, exhibited enhancement of clearance on CCl(4) treatment. When pretreated in vitro with AS and injected into normal mice, lipid A and R-type
LPS
showed a similar pattern of clearance of residual activities to the untreated forms, but S-type
LPS
exhibited enhancement of clearance. Comparison between different strains of mice revealed a correlation of AS content in liver and lipid A clearance, where the higher AS strain C3H/He mice showed a more rapid clearance than the lower AS strains C57BL/6 and BALB/c. Primary spheroid cultures of hepatocytes treated with 0.1 microM dexamethasone and 1 microM
glucagon
showed about a 2-fold increase in AS amount and a more rapid clearance of
LPS
from culture medium than untreated cells. These results suggest that AS in hepatocytes may be involved in the process of lipid A and
LPS
clearance and the extracellular leakage of AS may also participate in the systemic detoxification.
...
PMID:Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. 1838 19
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>